Christina DiArcangelo Puller is the CEO of Affinity BioCeuticals, Affinity Bio Partners, Affinity Patient Advocacy and Puller Racing has been recognized as the Top 100 Registry for Business Leaders and Professionals. Christina has forged a world-class reputation in the Biotechnology and Pharmaceutical industry for the past 20 years. Her engagements have led to numerous awards, keynote speaking engagements and the ultimate respect of her industry peers. Christina has managed several studies in the following therapeutic areas: Aesthetics, Plastics population includes Medicine, Pain Management, Oncology, Infectious Diseases, Endocrinology/Metabolic Diseases, Respiratory/Allergy/Pulmonary, Gastroenterology and Women’s Health. Through the course of Christina’s career, she has acted in various capacities for Global Clinical Research Organizations, Pharmaceutical Companies and Biotechnology Companies. Christina recently opened an office in the Bay Area in California for Affinity Bio Partners and Affinity BioCeuticals.
Christina’s professional success and drive as the founder and CEO of Affinity Bio Partners has been facilitated by her unwavering strength as a skilled negotiator, strategic advisor, visionary entrepreneur, skilled financial expert and her ability to success to navigate the pharmaceutical industry with unparalleled success. In addition, Christina is the Founder, President of the Board and CEO of Affinity Patient Advocacy, Affinity Patient Advocacy strives to provide families with independent, high-quality professional health management services, social services and wellness services. Affinity Patient Advocacy manages the process and help the patients and their family focus on the most important aspect of their treatment, getting better. Affinity Patient Advocacy’s mission is simple. Affinity Patient Advocacy strives to serve patients in their most important time of need. With that said, Affinity Patient Advocacy will become an invaluable resource to our clients. Patients who have been diagnosed with serious illnesses that require a treatment plan will receive comfort of mind in knowing that they have an advocate who will endeavor to remove the medical complexities and allow their family to focus all of their energies on treatments and recovery.
Christina’s newest venture, Affinity BioCeuticals, a “first of its kind” Cannabis Biotech Pennsylvania corporation. Affinity BioCeuticals is a Neutraceutical company focused on research and development of cannabinoid based therapies. Affinity BioCeuticals initially intends to focus its efforts on Opioid Abuse, PTSD, Anxiety and Oncology Supportive Care. The emergence of more and more indications where cannabinoid based treatment may be impactful to patient’s lives will be the primary focus for Affinity BioCeuticals. Affinity BioCeuticals will also be working on indications that are focused on meeting athletes needs and looks forward to working with retired NFL, NHL, and NBA players. Affinity BioCeuticals mission is to ensure that the Opioid Epidemic is beaten.Affinity BioCeuticals and Affinity Bio Partners will be hosting the First Medical Cannabis Clinical Symposium on December 8th in Philadelphia. Tickets can be purchased at https://www.eventbrite.com/publish?crumb=0c11cb4cfd157a&eid=38342380091 .